Core Viewpoint - 加科思-B (01167.HK) announced a share buyback on November 3, 2025, spending HKD 383,000 to repurchase 53,000 shares at a price range of HKD 7.18 to HKD 7.26 per share [1] Summary by Category - **Company Actions** - 加科思-B executed a buyback of 53,000 shares at a total cost of HKD 383,000 [1] - The buyback price per share ranged from HKD 7.18 to HKD 7.26 [1] - **Financial Implications** - The total expenditure for the buyback indicates a strategic move to enhance shareholder value [1] - The price range suggests a calculated approach to repurchase shares at a favorable valuation [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 若股份曾以超過一個每股價格發行/出售/購回/贖回，則須提供每股成交量加權平均價格。 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年11月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 ...

Core Insights - A total of 30 companies conducted share buybacks on October 30, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2] - The total buyback amount for China Feihe was 50.23 million yuan, with 12 million shares repurchased, representing a significant investment in its own stock [1][2] Summary by Company - **China Feihe (06186)**: Repurchased 12 million shares for 50.23 million yuan; cumulative buybacks for the year reached 30.95 million shares, accounting for 0.341% of total share capital [2] - **China Petroleum & Chemical Corporation (00386)**: Repurchased 4.78 million shares for 19.72 million yuan; cumulative buybacks for the year reached 102 million shares, accounting for 0.080% of total share capital [2] - **Stone Four Pharmaceutical Group (02005)**: Repurchased 5 million shares for 15.41 million yuan; cumulative buybacks for the year reached 44.20 million shares, accounting for 1.498% of total share capital [2] - **Lianlian Digital (02598)**: Repurchased 1.38 million shares for 11.31 million yuan; cumulative buybacks for the year reached 4.45 million shares, accounting for 1.065% of total share capital [2] - **Gushengtang (02273)**: Repurchased 290,100 shares for 8.33 million yuan; cumulative buybacks for the year reached 5.88 million shares, accounting for 2.482% of total share capital [2] - **Lianyi Technology-W (09959)**: Repurchased 2.3 million shares for 7.42 million yuan; cumulative buybacks for the year reached 80.04 million shares, accounting for 3.746% of total share capital [2] - **Mongolian Dairy (02319)**: Repurchased 400,000 shares for 5.70 million yuan; cumulative buybacks for the year reached 22.42 million shares, accounting for 0.573% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: Repurchased 280,000 shares for 4.21 million yuan; cumulative buybacks for the year reached 7.84 million shares, accounting for 9.216% of total share capital [2] - **Other Companies**: Various other companies also participated in buybacks, with amounts ranging from 4.51 million yuan to 6 million yuan, and share counts varying significantly [2]

Group 1 - The company, 加科思-B (01167), announced a share buyback plan [1] - The total expenditure for the buyback is HKD 496,000 [1] - The company plans to repurchase 69,000 shares [1]

Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Group 1 - The company will spend HKD 496,000 to repurchase 69,000 shares [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月30日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Group 1 - The company, 加科思-B (01167), announced a share buyback plan, spending approximately HKD 966,000 to repurchase 132,000 shares on October 28, 2025 [1]

Group 1 - The company, 加科思-B (01167), announced a share buyback plan, intending to repurchase approximately 132,000 shares at a cost of about HKD 966,000 on October 28, 2025 [1]

Summary of Key Points - The company, 加科思-B (01167.HK), announced a share buyback on October 28, 2025, spending HKD 966,000 to repurchase 132,000 shares at a price range of HKD 7.30 to HKD 7.35 per share [1]

表格類別： 股票 狀態： 新提交 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...